| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Chitopentaose pentahydrochloride targets chitinase B (FjchiB) as a substrate. It also targets immune cells, stimulating immune responses. The compound's antimicrobial and antioxidant properties suggest interactions with microbial cells and oxidative stress pathways. Its anti-inflammatory properties indicate modulation of inflammatory pathways. The compound is used in research on drug delivery, wound healing, and tissue engineering.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Chitopentaose pentahydrochloride is a substrate of chitinase B (FjchiB). The compound has anti-inflammatory properties and stimulates immune responses, promotes cell growth, and exhibits antimicrobial and antioxidant properties. It serves as a model compound in enzymatic degradation studies. These in vitro findings support its applications in immunology, antimicrobial research, and tissue engineering.
|
| ln Vivo |
In vivo studies of Chitopentaose pentahydrochloride are limited as the compound is primarily used as a research chemical. Its anti-inflammatory, antimicrobial, and tissue engineering applications suggest potential for in vivo evaluation in models of inflammation, infection, and wound healing. However, comprehensive in vivo pharmacological studies specifically targeting Chitopentaose pentahydrochloride are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme assays for Chitopentaose pentahydrochloride typically involve testing its activity as a substrate for chitinase B (FjchiB). Enzyme activity is measured by monitoring the degradation of the compound using chromatographic methods. Anti-inflammatory activity is assessed by measuring inhibition of inflammatory mediator production. Antimicrobial activity is assessed using standard disc diffusion or broth microdilution methods. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays for Chitopentaose pentahydrochloride involve culturing immune cells to evaluate its anti-inflammatory and immunomodulatory effects. Cells are treated with varying concentrations of the compound and cytokine production is measured. For antimicrobial studies, bacterial or fungal cultures are treated and cell viability is monitored. Cell viability is assessed using MTT or similar colorimetric assays. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Chitopentaose pentahydrochloride would be conducted to evaluate its anti-inflammatory, antimicrobial, and wound healing activities. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For wound healing studies, animal models of wound healing would be used. Parameters assessed would include wound closure, inflammatory markers, and histopathology. Control groups receiving vehicle alone would be included for comparison.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Chitopentaose pentahydrochloride reflect its nature as a chitosan oligosaccharide. It has the molecular formula C30H62Cl5N5O21. The compound is hygroscopic and should be stored under inert gas. As an oligosaccharide, it has limited oral bioavailability. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Chitopentaose pentahydrochloride has been evaluated in the context of its use as a research chemical. As a chitosan oligosaccharide, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of >95.0%. Proper handling procedures including protection from moisture are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References |
|
| Additional Infomation |
Chitopentaose pentahydrochloride (CAS# 117467-64-8) is also known as chitosan pentamer pentahydrochloride. It has the molecular formula C30H62Cl5N5O21. The compound is a chitosan oligosaccharide with anti-inflammatory properties. It is a substrate of chitinase B (FjchiB). Chitopentaose pentahydrochloride stimulates immune responses, promotes cell growth, and exhibits antimicrobial and antioxidant properties. It is used in research on drug delivery, wound healing, and tissue engineering.
|
| Molecular Formula |
C30H62CL5N5O21
|
|---|---|
| Molecular Weight |
1006.09918642044
|
| Exact Mass |
1005.235
|
| CAS # |
117467-64-8
|
| Related CAS # |
Chitotetraose tetrahydrochloride;117399-50-5;Chitobiose dihydrochloride;115350-24-8;Chitohexaose hexahydrochloride;127171-88-4;Chitoheptaose heptahydrochloride;127171-89-5;Chitotriose trihydrochloride;117436-78-9
|
| PubChem CID |
155903776
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
22
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
61
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
Cl.Cl.Cl.Cl.Cl.O([C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)N)O)N)[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)N)O
|
| InChi Key |
CQDWTALLCUNVFU-MNZPGXLZSA-N
|
| InChi Code |
InChI=1S/C30H57N5O21.5ClH/c31-7(1-36)17(43)23(8(42)2-37)53-28-14(33)20(46)25(10(4-39)50-28)55-30-16(35)22(48)26(12(6-41)52-30)56-29-15(34)21(47)24(11(5-40)51-29)54-27-13(32)19(45)18(44)9(3-38)49-27;;;;;/h1,7-30,37-48H,2-6,31-35H2;5*1H/t7-,8+,9+,10+,11+,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29-,30-;;;;;/m0...../s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-amino-4-[(2S,3R,4R,5S,6R)-3-amino-5-[(2S,3R,4R,5S,6R)-3-amino-5-[(2S,3R,4R,5S,6R)-3-amino-5-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5,6-trihydroxyhexanal;pentahydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (248.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9939 mL | 4.9697 mL | 9.9394 mL | |
| 5 mM | 0.1988 mL | 0.9939 mL | 1.9879 mL | |
| 10 mM | 0.0994 mL | 0.4970 mL | 0.9939 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
